Urinary Markers of Tubular Injury in Early Diabetic Nephropathy

International Journal of Nephrology

Volumn 2016, Issue , 2016, Pages

  Fiseha, Temesgen ^a   Tamir, Zemenu ^a  

^a WOLLO UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973370139     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2016/4647685     Document Type: Review

References (100)

1. T. Ninomiya, V. Perkovic, B. E. de Galan et al., "Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes," Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1813-1821, 2009.
2. P.-H. Groop, M. C. Thomas, J. L. Moran et al., "Thepresence and severity of chronic kidney disease predicts all-causemortality in type 1 diabetes," Diabetes, vol. 58, no. 7, pp. 1651-1658, 2009.
3. G. Targher, G. Zoppini, M. Chonchol et al., "Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals," Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 4, pp. 294-301, 2011.
4. R. C. Atkins and P. Zimmet, "Editorial: Diabetic kidney disease: act nowor pay later," Kidney International, vol. 77,no. 5, pp. 375-377, 2010.
5. K. Walczak, M. Sodolska, I. Materek, A. Krysicka, D. Moczulski, "Impaired renal function in type 2 diabetes patients in the absence of increased urine albumin excretion rate," Diabetologia Dóswiadczalna i Kliniczna, vol. 8, no. 4, pp. 165-168, 2008.
6. M. L. Caramori, P. Fioretto, M. Mauer, "Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions," Diabetes, vol. 52, no. 4, pp. 1036-1040, 2003.
7. P. Budhiraja, B. Thajudeen, M. Popovtzer, "Absence of albuminuria in type 2 diabetics with classical diabetic nephropathy: clinical pathological study," Journal of Biomedical Science and Engineering, vol. 6, no. 5, pp. 20-25, 2013.
8. J. Barratt and P. Topham, "Urine proteomics: the present and future of measuring urinary protein components in disease," Canadian Medical Association Journal, vol. 177, no. 4, pp. 361-368, 2007.
9. R. J. MacIsaac and G. Jerums, "Diabetic kidney disease with and without albuminuria," Current Opinion in Nephrology and Hypertension, vol. 20, no. 3, pp. 246-257, 2011.
10. M. C. Thomas,W. C. Burns,M. E. Cooper, "Tubular changes in early diabetic nephropathy," Advances in Chronic Kidney Disease, vol. 12, no. 2, pp. 177-186, 2005.
11. S. C. W. Tang and K. N. Lai, "The pathogenic role of the renal proximal tubular cell in diabetic nephropathy," Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3049-3056, 2012.
12. D. M. Gibb, P. A. Tomlinson, N. R. Dalton, C. Turner, V. Shah, T. M. Barratt, "Renal tubular proteinuria and microalbuminuria in diabetic patients," Archives of Disease in Childhood, vol. 64, no. 1, pp. 129-134, 1989.
13. S. C. W. Tang, J. C. K. Leung, K. N. Lai, "Diabetic tubulopathy: an emerging entity," Diabetes and the Kidney, vol. 170, pp. 124-134, 2011.
14. F. L. Nauta,W. E. Boertien, S. J. L. Bakker et al., "Glomerular and tubular damage markers are elevated in patients with diabetes," Diabetes Care, vol. 34, no. 4, pp. 975-981, 2011.
15. J. V. Bonventre, "Can we target tubular damage to prevent renal function decline in diabetes" Seminars in Nephrology, vol. 32, no. 5, pp. 452-562, 2012.
16. V. S. Vaidya,M. A. Niewczas, L. H. Ficociello et al., "Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, N-acetyl-D-glucosaminidase," Kidney International, vol. 79, no. 4, pp. 464-470, 2011.
17. A. Lacquaniti, V. Donato, B. Pintaudi et al., "'Normoalbuminuric' diabetic nephropathy: tubular damage and NGAL," Acta Diabetologica, vol. 50, no. 6, pp. 935-942, 2013.
18. S. Abd El Dayem, A. E. El Bohy, A. El Shehaby, "Value of the intrarenal arterial resistivity indices and different renal biomarkers for early identification of diabetic nephropathy in type 1 diabetic patients," Journal of Pediatric Endocrinology and Metabolism, vol. 29, no. 3, pp. 273-279, 2015.
19. J. A. de Carvalho, E. Tatsch, B. S. Hausen et al., "Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes," Clinical Biochemistry, vol. 49, no. 3, pp. 232-236, 2016.
20. K. Mori and K. Nakao, "Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage," Kidney International, vol. 71, no. 10, pp. 967-970, 2007.
21. S. S. Kim, S. H. Song, I. J. Kim et al., "Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients,"Diabetes Research and Clinical Practice, vol. 97, no. 2, pp. 251-257, 2012.
22. S. E. Nielsen, K. J. Schjoedt, A. S. Astrup et al., "Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril," Diabetic Medicine, vol. 27, no. 10, pp. 1144-1150, 2010.
23. M. H. Hafez, F. A. F. El-Mougy, S. H. Makar, S. S. Abd El Shaheed, "Detection of an earlier tubulopathy in diabetic nephropathy among children with normoalbuminuria," Iranian Journal of Kidney Diseases, vol. 9, no. 2, pp. 126-131, 2015.
24. Z. Yrk Yldrm, A. Nayr, A. Ylmaz, A. Gedikbas-, R. Bundak, "Neutrophil gelatinase-associated lipocalin as an early sign of diabetic kidney injury in children," Journal of Clinical Research in Pediatric Endocrinology, vol. 7, no. 4, pp. 274-279, 2015.
25. H. S. Assal, S. Tawfeek, E. A. Rasheed, D. El-Lebedy, E. H. Thabet, "Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus," Clinical Medicine Insights: Endocrinology and Diabetes, vol. 6, pp. 7-13, 2013.
26. D. Bolignano, A. Lacquaniti, G. Coppolino et al., "Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients," Kidney and Blood Pressure Research, vol. 32, no. 2, pp. 91-98, 2009.
27. W.-J. Fu, S.-L. Xiong, Y.-G. Fang et al., "Urinary tubular biomarkers in short-termtype 2 diabetes mellitus patients: a crosssectional study," Endocrine, vol. 41, no. 1, pp. 82-88, 2012.
28. J. Zachwieja, J. Soltysiak, P. Fichna et al., "Normal-range albuminuria does not exclude nephropathy in diabetic children," Pediatric Nephrology, vol. 25, no. 8, pp. 1445-1451, 2010.
29. A. A. Al-Refai, S. I. Tayel, A. Ragheb, A. G. Dala, A. Zahran, "Urinary neutrophil gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria," Open Journal of Nephrology, vol. 4, no. 1, pp. 37-46, 2014.
30. V. Garg, M. Kumar, H. S. Mahapatra, A. Chitkara, A. K. Gadpayle, V. Sekhar, "Novel urinary biomarkers in pre-diabetic nephropathy," Clinical and Experimental Nephrology, vol. 19, no. 5, pp. 895-900, 2015.
31. K. Demir, A. Abaci, T. Kme,A. Altincik, G. Ctli, E. Bber, "Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents," Journal of Pediatric Endocrinology and Metabolism, vol. 25, no. 5-6, pp. 517-523, 2012.
32. A. Ucakturk, B. Avci, G. Genc, O. Ozkaya, M. Aydin, "Kidney injury molecule-1 and neutrophil gelatinase associated lipocalin in normoalbuminuric diabetic children," Journal of Pediatric Endocrinology and Metabolism, vol. 29, no. 2, pp. 145-151, 2015.
33. J. Wu, Y. Ding, C. Zhu et al., "Urinary TNF-and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes," Experimental andTherapeuticMedicine, vol. 6, no. 6, pp. 1482-1488, 2013.
34. S. E. Nielsen, H. Reinhard, D. Zdunek et al., "Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients,"Diabetes Research and Clinical Practice, vol. 97, no. 1, pp. 71-76, 2012.
35. G. D. Fufaa,E. J. Weil, R. G. Nelson et al., "Associationof urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus," Diabetologia, vol. 58, no. 1, pp. 188-198, 2015.
36. J. V. Bonventre, "Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more," Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3265-3268, 2009.
37. W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, J. V. Bonventre, "Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury," Kidney International, vol. 62, no. 1, pp. 237-244, 2002.
38. A. C. Carlsson, M. Calamia, U. Risrus et al., "Kidney injury molecule (KIM)-1 is associated with insulin resistance: results from two community-based studies of elderly individuals," Diabetes Research and Clinical Practice, vol. 103, no. 3, pp. 516-521, 2014.
39. N. E. El-Ashmawy, E. A. El-Zamarany, N. F. Khedr, A. I. AbdEl-Fattah, S. A. Eltoukhy, "Kidney injury molecule-1 (Kim-1): an early biomarker for nephropathy in type II diabetic patients," International Journal of Diabetes in Developing Countries, vol. 35, no. S3, pp. 431-438, 2015.
40. B. R. Conway, D. Manoharan, D. Manoharan et al., "Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors," Kidney International, vol. 82, no. 7, pp. 812-818, 2012.
41. B. K. Tekce, H. Tekce, G. Aktas, M. Sit, "Evaluation of the urinary kidney injury molecule-1 levels in patients with diabetic nephropathy," Clinical and Investigative Medicine, vol. 37, no. 6, pp. E377-E383, 2014.
42. S. A. Ahmed and M. A. Hamed, "Kidney injury molecule-1 as a predicting factor for inflamed kidney, diabetic and diabetic nephropathy Egyptian patients," Journal of Diabetes and Metabolic Disorders, vol. 14, no. 1, article 6, 2015.
43. S. E. Nielsen, K. Rossing, G. Hess et al., "The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: U-NGAL, u-KIM1 and u-LFABP," Scandinavian Journal of Clinical and Laboratory Investigation, vol. 72, no. 2, pp. 137-142, 2012.
44. A. Kamijo, T. Sugaya, A. Hikawa et al., "Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules," American Journal of Pathology, vol. 165, no. 4, pp. 1243-1255, 2004.
45. A. Kamijo, T. Sugaya, A. Hikawa et al., "Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease," Molecular and Cellular Biochemistry, vol. 284, no. 1-2, pp. 175-182, 2006.
46. M. Von Eynatten, M. Baumann, U. Heemann et al., "Urinary LFABP and anaemia: distinct roles of urinary markers in type 2 diabetes," European Journal of Clinical Investigation, vol. 40, no. 2, pp. 95-102, 2010.
47. T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, H. Koide, "Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy," Diabetes Care, vol. 28,no. 11,pp. 2728-2732, 2005.
48. S. E. Nielsen, T. Sugaya, L. Tarnow et al., "Tubular and glomerular injury in diabetes and the impact of ACE inhibition," Diabetes Care, vol. 32, no. 9, pp. 1684-1688, 2009.
49. K. Suzuki, T. Babazono, H. Murata, Y. Iwamoto, "Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy," Diabetes Care, vol. 28, no. 8, pp. 2038-2039, 2005.
50. V. Viswanathan, S. Sivakumar, V. Sekar, D. Umapathy, S. Kumpatla, "Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy," Indian Journal of Nephrology, vol. 25, no. 5, pp. 269-273, 2015.
51. S.-I. Araki, M. Haneda, D. Koya et al., "Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy," Diabetes Care, vol. 36, no. 5, pp. 1248-1253, 2013.
52. S. E. Nielsen, T. Sugaya, P. Hovind, T. Baba, H.-H. Parving, P. Rossing, "Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients," Diabetes Care, vol. 33, no. 6, pp. 1320-1324, 2010.
53. N. M. Panduru, C. Forsblom, M. Saraheimo et al., "Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes," Diabetes Care, vol. 36, no. 7, pp. 2077-2083, 2013.
54. A. Kamijo-Ikemori, T. Sugaya, T. Yasuda et al., "Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients," Diabetes Care, vol. 34, no. 3, pp. 691-696, 2011.
55. S. Sklov, "The diagnostic role of urinary N-acetyl-beta-Dglucosaminidase (NAG) activity in the detection of renal tubular impairment," Acta Medica, vol. 48, no. 2, pp. 75-80, 2005.
56. S. Uslu, B. Efe, O. Alataset al., "Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients," Journal of Nephrology, vol. 18, no. 5, pp. 559-567, 2005.
57. B. R. Bouvet, C. V. Paparella, S. M. M. Arriaga, A. L. Monje, A. M. Amarilla, A. M. Almar, "Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus," Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 58, no. 8, pp. 798-801, 2014.
58. F. P. Udomah, U. E. Ekrikpo, E. Effa, B. Salako, A. Arije, S. Kadiri, "Association between urinary N-acetyl-beta-D-glucosaminidase and microalbuminuria in diabetic black Africans," International Journal of Nephrology, vol. 2012,Article ID 235234, 5 pages, 2012.
59. G. Sheira, N. Noreldin, A. Tamer, M. Saad, "Urinary biomarker N-acetyl-D-glucosaminidase can predict severity of renal damage in diabetic nephropathy," Journal of Diabetes and Metabolic Disorders, vol. 14, article 4, 2015.
60. A. Mohammadi-Karakani, S. Asgharzadeh-Haghighi, M. Ghazi-Khansari, R. Hosseini, "Determination of urinary enzymes as a marker of early renal damage in diabetic patients," Journal of Clinical Laboratory Analysis, vol. 21, no. 6, pp. 413-417, 2007.
61. G. Nikolov, M. Boncheva, T. Gruev, S. Biljali, O. Stojceva-Taneva, E. Masim-Spasovska, "Urinary biomarkers in the early diagnosis of renal damage in diabetes mellitus patients," Scripta Scientifica Medica, vol. 45, no. 3, pp. 58-64, 2013.
62. W. K. Gatua, J. N. Makumi, E. M. Njagi, C. S. Kigondu, S. O. Mcligeyo, S. K. Waithaka, "Evaluation of urinary tubular enzymes as screening markers of renal dysfunction in patients suffering from diabetes mellitus," Asian Journal of Medical Sciences, vol. 3, no. 3, pp. 84-90, 2011.
63. R. Bansal, D. Lahon, B. B. Thakur, A. Saikia, "A study of urinary enzymes as a marker of early renal damage in patients suffering from diabetes mellitus," Indian Journal of Basic & Applied Medical Research, vol. 4, no. 4, pp. 768-776, 2015.
64. V. Ambade, P. Singh, B. L. Somani, D. Basannar, "Urinary N-acetyl beta glucosaminidase and gammaglutamyl transferase as early markers of diabetic nephropathy," Indian Journal of Clinical Biochemistry, vol. 21, no. 2, pp. 142-148, 2006.
65. V. Vlatkovi, B. Stojimirovi, R. Obrenovi, "Damage of tubule cells in diabetic nephropathy type 2: urinary N-acetyl-D-glucosaminidasis and-glutamil-transferasis," Vojnosanitetski Pregled, vol. 64, no. 2, pp. 123-127, 2007.
66. V. Vlatkovi, B. Stojimirovi, R. Obrenovi, S. Nogi, "Damage to proximal tubular epithelial cells in type 2 diabetes mellitus,"Medicinski pregled, vol. 60, no. 5-6, pp. 272-276, 2007.
67. D. N. Patel and K. Kalia, "Efficacy of urinary N-acetyl-Dglucosaminidase to evaluate early renal tubular damage as a consequence of type 2 diabetes mellitus: a cross-sectional study," International Journal of Diabetes in Developing Countries, vol. 35, no. 3, supplement, pp. 449-457, 2015.
68. A. Piwowar, M. Knapik-Kordecka, I. Fus,M. Warwas, "Urinary activities of cathepsin B, N-acetyl-D-glucosaminidase, albuminuria in patients with type 2 diabetes mellitus," Medical ScienceMonitor, vol. 12, no. 5, pp. CR210-CR214, 2006.
69. E. F. O. Kern, P. Erhard, W. Sun, S. Genuth, M. F. Weiss, "Early urinarymarkers of diabetic kidney disease: a nested casecontrol study from the diabetes Control and Complications Trial (DCCT)," American Journal of Kidney Diseases, vol. 55, no. 5, pp. 824-834, 2010.
70. O. Bakoush, A. Grubb, B. Rippe, J. Tencer, "Urine excretion of protein HC in proteinuric glomerular diseases correlates to urine IgG but not to albuminuria," Kidney International, vol. 60, no. 5, pp. 1904-1909, 2001.
71. N. Shore, R. Khurshid, M. Saleem, "Alpha-1 microglobulin: a marker for early detection of tubular disorders in diabetic nephropathy," Journal of AyubMedical College, vol. 22, no. 4, pp. 53-55, 2010.
72. L. Petrica, A. Vlad, G. Gluhovschi et al., "Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus," International Journal of Clinical and Experimental Medicine, vol. 8, no. 2, pp. 2516-2525, 2015.
73. A. Saif andN. Soliman, "Urinary 1-microglobulin and albumin excretion in children and adolescents with type 1 diabetes," Journal of Diabetes, 2016.
74. E. Korpinen, A.-M. Teppo, L. Hukkanen, H. K. Akerblom, C. Grnhagen-Riska, O. Vaarala, "Urinary transforming growth factor-1 and 1-microglobulin in children and adolescents with type 1 diabetes," Diabetes Care, vol. 23,no. 5, pp. 664-668, 2000.
75. C.-Y. Hong, K. Hughes, K.-S. Chia, V. Ng, S.-L. Ling, "Urinary 1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore," Diabetes Care, vol. 26, no. 2, pp. 338-342, 2003.
76. L. Petrica, A. Vlad, G. Gluhovschi et al., "Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study," PLoS ONE, vol. 9, no. 11, Article ID e112538, 2014.
77. S. Jain, A. Rajput, Y. Kumar, N. Uppuluri, A. S. Arvind, U. Tatu, "Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder," Journal of Association of Physicians of India, vol. 53, pp. 513-520, 2005.
78. A. Kalansooriya, I. Holbrook, P. Jennings, P. H. Whiting, "Serum cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 diabetes," British Journal of Biomedical Science, vol. 64, no. 3, pp. 121-123, 2007.
79. M. L. Robles-Osorio and E. Sabath, "Tubular dysfunction and non-albuminuric renal disease in subjects with type 2 diabetes mellitus," Revista de Investigacion Clinica, vol. 66,no. 3, pp. 234-239, 2014.
80. L. Petrica, M. Petrica, A. Vlad et al., "Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetesmellitus: a cross-sectional study," Nephron Clinical Practice, vol. 118, no. 2, pp. c155-c164, 2011.
81. L. Petrica, M. Petrica, A. Vlad et al., "Nephro-and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial,"WienerKlinischeWochenschrift, vol. 121, no. 23-24, pp. 765-775, 2009.
82. L. Petrica, A. Vlad, M. Petrica et al., "Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetesmellitus," Diabetes Research and Clinical Practice, vol. 94, no. 1, pp. 22-32, 2011.
83. D. A. Brott, S. T. Furlong, S. H. Adler et al., "Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes," Drug Design, Development and Therapy, vol. 9, pp. 3191-3198, 2015.
84. X. Zeng, D. Hossain,D. G. Bostwick, G. A. Herrera, B. Ballester, P. L. Zhang, "Urinary 2-microglobulin is a sensitive indicator for renal tubular injury," Scholarena Journal (SAJ) of Case Reports, vol. 1, no. 1, pp. 1-6, 2014.
85. C. Y. Hong, K. S. Chia, S. L. Ling, "Urine protein excretion among Chinese patients with type 2 diabetes mellitus," The Medical Journal of Malaysia, vol. 55, no. 2, pp. 220-229, 2000.
86. N. Aghamohammadzadeh, A. A. Abolfathi, A. Alizadeh, H. Ghasemi, "Evaluation of microalbuminuria and urine beta 2 microglobulin in patients with type 1 and 2 diabetes," International Journal of Current Research and Academic Review, vol. 3, no. 6, pp. 451-462, 2015.
87. M. A. Fathy,M. M. Elkady, H. A. Fathy, S. A. Awad, A. A. Elmenshawy, "Estimation of renal tubular markers for predicting early stage diabetic nephropathy in Egyptian children with type I dibetes mellitus," Research Journal ofMedical Sciences, vol. 4, no. 2, pp. 207-211, 2009.
88. C. Y. Hong, K. S. Chia,S. L. Ling, "Urinaryproteinexcretion in Type 2 diabetes with complications," Journal of Diabetes and its Complications, vol. 14, no. 5, pp. 259-265, 2000.
89. M. Papale, S. Di Paolo, R. Magistroni et al., "Urine proteome analysis may allownoninvasive differential diagnosis of diabetic nephropathy," Diabetes Care, vol. 33, no. 11, pp. 2409-2415, 2010.
90. X. Rao, M. Wan, C. Qiu, C. Jiang, "Role of cystatin C in renal damage and the optimum cut-off point of renal damage among patients with type 2 diabetesmellitus," Experimental and Therapeutic Medicine, vol. 8, no. 3, pp. 887-892, 2014.
91. K. Mise, J. Hoshino, T. Ueno et al., "Prognostic value of tubulointerstitial lesions, urinary N-acetyl-D-glucosaminidase, urinary 2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy,"Clinical Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 593-601, 2016.
92. H. Dihazi, G. A. Mller, S. Lindner et al., "Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients," Clinical Chemistry, vol. 53, no. 9, pp. 1636-1645, 2007.
93. K. Takebayashi, M. Suetsugu, S. Wakabayashi, Y. Aso, T. Inukai, "Retinol binding protein-4 levels and clinical features of type 2 diabetes patients," Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2712-2719, 2007.
94. E. Novery, S. Susanah, D. Rachmadi, "The correlation of urine retinol binding protein-4 and serum HbA1c with glomerular filtration rate in type 1 (insulin-dependent) diabetic children: a perspective on the duration of diabetes," Open Journal of Pediatrics, vol. 5, no. 2, pp. 134-140, 2015.
95. M. A. K. Salem, S. A. El-Habashy, O. M. Saeid, M. M. K. El-Tawil, P. H. Tawfik, "Urinary excretion of n-acetyl-D-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus," Pediatric Diabetes, vol. 3, no. 1, pp. 37-41, 2002.
96. A. A. S. Abdallah, K. A. El-Shamy,W. M. Morcos, T. H. Mikhail, N. N. Fadl, "Early marker for renal impairment and angiopathy in diabetic Egyptian children," Life Science Journal, vol. 8, no. 3, pp. 358-366, 2011.
97. N. Zahra, M. A. Javad, N. Aboalfazl, "Detection of early stage renal disease by elevation of certain lowmolecularWeight proteins in urine of diabetes patients," International Journal of Biological Sciences and Applications, vol. 1, no. 1, pp. 15-18, 2014.
98. S. E. Park, N. S. Lee, J. W. Park et al., "Association of urinary RBP4 with insulin resistance, inflammation, microalbuminuria," European Journal of Endocrinology, vol. 171, no. 4, pp. 443-449, 2014.
99. S. M. Titan, J. M. Vieira Jr., W. V. Dominguez et al., "Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy," Journal of Diabetes and its Complications, vol. 26, no. 6, pp. 546-553, 2012.
100. C. Catalano, P. H. Winocour, S. Parlongo, I. Gibb, S. Gillespie, K. G. M. M. Alberti, "Measures of tubular function in normoalbuminuric insulin-dependent diabetic patients and their relationship with sodium lithium countertransport activity," Nephron, vol. 73, no. 4, pp. 613-618, 1996.